March 28, 2017
Unison Capital, Inc.
Notice regarding Acquisition of 16 Long Listed Products from Astellas Pharma Inc.
We are pleased to announce that on March 28, 2017, LTL Pharma Co., Ltd. (“LTL Pharma”), a whollyowned
subsidiary of Japan Established Medicines Corporation (“JEMCO”) which was established by Unison
Capital Partners IV, LPS and Unison Capital Partners IV(F), L.P. (collectively, “Unison”), has entered into an
asset purchase agreement with Astellas Pharma Inc. (“Astellas”) under which Astellas will transfer the
ownership and rights associated with 16 long-listed products to LTL Pharma.
Faced with heightened expectations for new drug development, an increasing number of pharmaceutical
companies are employing the strategic move to divest their portfolio of long-listed products (“LLPs”) in order
to concentrate their capital and resources on new drug development. Meanwhile, LLPs continue to play an
important role in society alongside generic drugs.
Leveraging prior experiences in the pharmaceutical industry, Unison aims to provide a platform through
which LLPs are stably supplied and distributed to patients and medical institutions over the long-term. Such
initiative enables Unison to simultaneously contribute to two critical societal needs - the acceleration of new
drug development by pharmaceutical companies and long-term stable supply of LLPs. Through JEMCO,
Unison will support the expansion of LTL Pharma’s product portfolio by actively seeking opportunities to
acquire LLPs from various pharmaceutical companies.
Please direct all inquiries concerning this matter to: